Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth

Company Overview - Defence Therapeutics Inc. is a clinical-stage biotechnology company focused on drug delivery technologies, particularly in developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [5]. Leadership Appointment - Dr. Amie Phinney has been appointed as the Strategy & Business Advisor to guide Defence Therapeutics in its next phase of growth, effective immediately [1]. - Dr. Phinney brings over 20 years of experience in life sciences commercialization, having held significant roles in pharmaceutical R&D and biotech innovation at companies like Abbott and AbbVie [2][3]. Strategic Vision - The company is at a pivotal point, with its scientific advancements opening new transformative opportunities. Dr. Phinney's expertise in both scientific and strategic leadership is expected to help the company capture this momentum for sustainable growth [4]. - Dr. Phinney expressed enthusiasm about joining Defence Therapeutics, highlighting the potential of the company's science to transform the field of antibody-delivered therapeutics and her commitment to building a roadmap for innovation [4].